This is a copy of the June 24th edition of our weekly Newsletter, which we have been publishing since October, 2015.
Barring an unexpected decision from the FDA, GW Pharma, which will hear from the agency by Wednesday, will make history this week when it receives approval for Epidiolex, its oral CBD solution that treats the seizures caused by rare forms of epilepsy. While the FDA has approved synthetic THC previously, this will be the first FDA-approved drug derived from the cannabis plant.
Epidiolex approval will be not only a victory for GW Pharma but also a major milestone for the legalization movement. For years, cannabis has been seen by the federal government as dangerous and having no medical benefits, but clearly that is not the case, according to the advisory committee that reviewed Epidiolex and recommended that the FDA approve it.
We have seen some confusion about what might happen if Epidiolex is approved.After FDA approval, the DEA can take up to 90 days to schedule it, and then the company will begin to market it. Some have mistakenly concluded that the DEA must reschedule cannabis, but this is not the case. The approval of Epidiolex will have no direct impact on the current Schedule 1 status, but it sure seems like it would be great evidence in a court case should someone sue the federal government.
Investors have made bets on GW Pharma, and it’s not clear how much the approval is priced in, but the more interesting exercise is to assess how FDA approval of a cannabis-derived pharmaceutical will impact the overall industry. Some fear, incorrectly we believe, that this could be a threat to the dispensary model, but this ignores the history of fish oil, which has pharmaceutical and over-the-counter products that coexist. We think that the success of GW Pharma will spur investors to fund other companies pursuing the FDA path. This is already happening to some degree, but we think the approval of Epidiolex will accelerate the trend.
To learn more about Liberty Health Sciences, visit the company’s Investor Dashboard that we maintain on its behalf, click the blue Follow Company button in order to stay up to date with their progress.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Aurora Cannabis to Spin-Off U.S. Cannabis Company, Australis Capital
- Bhang to Raise up to $10 Million Ahead of Going Public in Canada
- California Premium Cannabis Grower Canndescent Named to Exclusive Startup List
- Canadian Cannabis Producer Tilray to Go Public on the NASDAQ
- Constellation Brands Takes 1/3 of Canopy Growth Convertible Note Deal
- Emblem Enters German Medical Cannabis Market
- Exclusive: German Securities Clearance Firm Pulls Plug on North American Cannabis Stocks
- Horizons Expands Cannabis Investing Options with Derivative Securities
- MedReleaf Generates $12 Million in Sales in Q4
- TGOD Boosts Capacity by 30%, Targeting Cannabis Beverages and Edibles Production
To get real-time updates download our free mobile app for Android or Appledevices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers.
View the Public Cannabis Company Revenue Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5m per quarter.
Consider subscribing to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013 for more in-depth information and market intelligence about the publicly traded cannabis sector, including insights into Canadian, American, German and Australian opportunities.
Discover your place in the cannabis industry by visiting our Careers and Jobs Page and learn which companies are hiring aggressively.
Alan & Joel